A detailed history of Soleus Capital Management, L.P. transactions in Inhibrx, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 267,871 shares of INBX stock, worth $3.8 Million. This represents 0.77% of its overall portfolio holdings.

Number of Shares
267,871
Previous 15,000 1685.81%
Holding current value
$3.8 Million
Previous $570,000 1542.81%
% of portfolio
0.77%
Previous 0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $8.28 Million - $10 Million
252,871 Added 1685.81%
267,871 $9.36 Million
Q4 2023

Feb 14, 2024

SELL
$14.5 - $38.0 $7.75 Million - $20.3 Million
-534,183 Reduced 97.27%
15,000 $570,000
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $1.2 Million - $2 Million
76,000 Added 16.06%
549,183 $10.1 Million
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $596,669 - $978,735
35,181 Added 8.03%
473,183 $12.3 Million
Q1 2023

May 15, 2023

SELL
$18.45 - $27.14 $743,535 - $1.09 Million
-40,300 Reduced 8.43%
438,002 $8.27 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $2.31 Million - $3.81 Million
114,400 Added 31.44%
478,302 $11.8 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $4.21 Million - $9 Million
363,902 New
363,902 $6.53 Million
Q4 2021

Feb 14, 2022

SELL
$26.75 - $46.02 $2.62 Million - $4.51 Million
-97,979 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$25.18 - $37.81 $3.65 Million - $5.48 Million
-144,810 Reduced 59.64%
97,979 $3.26 Million
Q2 2021

Aug 16, 2021

SELL
$14.69 - $27.52 $2.33 Million - $4.37 Million
-158,704 Reduced 39.53%
242,789 $6.68 Million
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $3.05 Million - $7.74 Million
187,686 Added 87.78%
401,493 $8.06 Million
Q4 2020

Feb 16, 2021

SELL
$15.96 - $50.0 $3.08 Million - $9.63 Million
-192,693 Reduced 47.4%
213,807 $7.05 Million
Q3 2020

Nov 13, 2020

BUY
$16.77 - $20.65 $6.82 Million - $8.39 Million
406,500 New
406,500 $7.32 Million

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.